Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors

Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)

A Study of PLX2853 in Advanced Malignancies.

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies